MENU
MRVI
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

MRVI stock forecast, quote, news & analysis

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease... Show more

MRVI
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for MRVI with price predictions
Oct 01, 2026

Aroon Indicator for MRVI shows an upward move is likely

MRVI's Aroon Indicator triggered a bullish signal on September 04, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 171 similar instances where the Aroon Indicator showed a similar pattern. In 156 of the 171 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on MRVI as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for MRVI just turned positive on September 24, 2026. Looking at past instances where MRVI's MACD turned positive, the stock continued to rise in 35 of 48 cases over the following month. The odds of a continued upward trend are 73%.

MRVI moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +0.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 207 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for MRVI moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 20 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.556) is normal, around the industry mean (26.780). P/E Ratio (28.333) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was -2%. KOD experienced the highest price growth at 196%, while CDT experienced the biggest fall at -59%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
MRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
10770 Wateridge Circle
Phone
+1 858 546-0004
Employees
435
Web
https://www.maravai.com
Aroon Indicator for MRVI shows an upward move is likely